Date: 2017-08-30
Type of
information: Submission of a clinical trial application
phase: 1b/2
Announcement: submission of a clinical trial application
Company: Molecular Partners (Switzerland)
Product: MP0250 and osimertinib (Tagrisso®)
Action
mechanism:
- protein/DARPIN/kinase inhibitor/tyrosine kinase inhibitor. MP0250 is a multi-DARPin® product consisting of four domains targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) and also binds to human serum albumin (HSA) to increase the plasma half-life and potentially tissue penetration.
- Osimertinib is an irreversible inhibitor of epidermal growth factor receptors that harbour sensitising mutations (EGFRm) and TKI-resistance mutation T790M. Nearly two out of three patients with NSCLC whose disease progresses after treatment with an EGFR inhibitor develop the T790M mutation, for which treatment options are limited. A small number of patients (approximately 3-5%) have the T790M mutation at NSCLC diagnosis.
- The combination of MP0250 with osimertinib is expected to continuously block the EGFR-mutated pathway and simultaneously inhibit two additional non-EGFR related pathways of resistance.
Disease:
Therapeutic
area: Cancer - Oncology
Country: USA
Trial
details: EGFR-mutated T790M-positive Non-Small Cell Lung Cancer (NSCLC)
Latest
news:
- • On August 30, 2017. Molecular Partners announced that MP0250 will be further evaluated in solid tumors. In August, the company submitted to the FDA an Investigational New Drug Application (IND) for a phase 1b/2 trial of MP0250 in combination with osimertinib (Tagrisso®) in EGFR-mutated T790M-positive Non-Small Cell Lung Cancer (NSCLC) patients.
Is
general: Yes
